Drugs / JZP441
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06961266 | May 2025 → Jan 2026 | narcolepsy | Jazz Pharmaceuticals | Terminated | No outcome recorded Stop: Business |
| Phase 1 | NCT05720494 | Jan → Sep 2023 | — | Jazz Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT05651152 | Nov 2022 → Nov 2023 | — | Jazz Pharmaceuticals | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | JZP441 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05720494 ↗ |
| Route | Oral | “oral dose of JZP441” NCT05651152 ↗ |